Highlights • A subset of patients experienced persistent fatigue symptoms after COVID-19. • Treatment with low-dose naltrexone (LDN) and NAD+ was well tolerated. • Treatment increased SF-36 quality of life scores. • Treatment also improved fatigue symptom scores. • A subset of patients were clinically responsive.
All Keywords
【저자키워드】 COVID-19, fatigue, Long COVID, Quality of life, NAD+, SF-36, Low dose naltrexone,
【저자키워드】 COVID-19, fatigue, Long COVID, Quality of life, NAD+, SF-36, Low dose naltrexone,